Fermer
Loading
Fermer

Fermer
On commande un document pour l'utiliser en classe. Notez que l'utilisation de certains cas est payante. Ces cas sont facilement repérables par les logos qui renvoient à nos partenaires commerciaux. Lorsque vous voulez utiliser un de ces cas en contexte pédagogique, vous êtes redirigé vers le partenaire commercial avec lequel vous effectuerez la transaction.

Cipla Global Ltd.: Generics versus Drug Discovery

Cas 9 40 2015 025
Cas publié dans la Revue internationale de cas en gestion, vol. 13, no 4
Auteurs : 
Langues : 
  • Anglais
Mots clés: 
  • Generics manufacturer,
  • Pharmaceutical industry,
  • Intellectual property rights,
  • Growth strategy,
  • Indian multinational
Année de production : 
2015
Date de dépôt : 
2015-12-07
Notes pédagogiques incluses : 
Oui
Résumé

Cipla Global Ltd. (CGL) is a real-life, undisguised decision case. CGL is one of India’s top pharmaceutical companies. Thanks to India’s process patent regime (1970–2005), Dr. Yusuf Hamied, the company’s chairman, managed to catapult the company to its position as a leading generics manufacturer. However, in 2005, India changed its Patents Act to make it TRIPS compliant. Faced with Western pharmaceutical companies’ ‘evergreening’, CGL became a prominent crusader against multinationals. It fought and won patent cases in Indian courts. On the other hand, the government of India took advantage of the TRIPS provisions to authorize Indian companies to manufacture copies of patented drugs without the patent holder’s permission. This infuriated Western pharmaceutical companies because they saw this provision as an infringement on their rights, which would lead to decreased revenues. As a consequence, they started lobbying their respective governments to put pressure on the Indian government. The case ends with a dilemma about the best course of action for CGL going forward, given the various options offered by the industry, on the one hand, and the ambitions of its chairman, on the other.

Discipline principal : 
Management  - Stratégie
Discipline secondaire : 
Non disponible
Secteurs d'activité : 
  • Santé
Provenance : 
Ailleurs
Type : 
Cas traditionnel (Cas descriptif)
Type de données pour la production du cas : 
Données réelles, publiques, libres de toute matière litigieuse
Lieu de l'événement : 
India
Année de début de l'événement : 
2015
Année de fin de l'événement : 
Non disponible
Taille de l'entreprise : 
Grande entreprise
Principaux thèmes couverts
  • Trends and trade in the global pharmaceutical industry;
  • Global pharmaceutical value chain patent laws, their impact on the Indian pharmaceutical sector;
  • The Indian pharmaceutical industry: nature and competitive dynamics;
  • Cipla Ltd.’s positioning and the consequent fall out.
Objectifs pédagogiques
  • Determine the various issues facing a relatively small company in an emerging market, but with international aspirations.
  • Appreciate the existence of several strategic groups in the industry, as well as their business models and value chains – being part of a strategic group has implications for growing the business, as does the presence of mobility barriers that hinder movement from one strategic group to another.
  • Understand the global context.
  • Comprehend how a company arrives at one or more strategies that will propel it to become a fairly large globally oriented entity in a relatively short timeframe.
Concepts et théories en lien avec le cas
  • Environmental changes and their impact on the business strategy of a pharmaceutical company.
  • Cost dynamics: how they can help a domestic generics company to go global.
  • Regional strategies that can assist a company to internationalize its operations and complement its efforts to become an MNC manufacturing and marketing generics.